Search Results - "O'Gorman, Melissa T."

Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study by Chen, Joseph, O’Gorman, Melissa T., James, Lee P., Klamerus, Karen J., Mugundu, Ganesh, Pithavala, Yazdi K.

“…Background Lorlatinib demonstrated efficacy (including intracranial activity) in patients with anaplastic lymphoma kinase ( ALK )-positive non-small cell lung…”
Get full text

Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals by Wang, Xiaoxing, Dowty, Martin E., Wouters, Ann, Tatulych, Svitlana, Connell, Carol A., Le, Vu H., Tripathy, Sakambari, O’Gorman, Melissa T., Winton, Jennifer A., Yin, Natalie, Valdez, Hernan, Malhotra, Bimal K.

“…Background and Objective Abrocitinib is a Janus kinase 1-selective inhibitor for the treatment of moderate-to-severe atopic dermatitis. Abrocitinib is…”
Get full text

Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals by Wang, Xiaoxing, Dowty, Martin E., Tripathy, Sakambari, Le, Vu H., Huh, Yeamin, Curto, Madelyn, Winton, Jennifer A., O’Gorman, Melissa T., Chan, Gary, Malhotra, Bimal K.

“…Background and Objective Abrocitinib is an oral small-molecule Janus kinase (JAK)-1 inhibitor approved for the treatment of moderate-to-severe atopic…”
Get full text

Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects by Johnson, Theodore R., Tan, Weiwei, Goulet, Lance, Smith, Evan B., Yamazaki, Shinji, Walker, Gregory S., O'Gorman, Melissa T., Bedarida, Gabriella, Zou, Helen Y., Christensen, James G., Nguyen, Leslie N., Shen, Zhongzhou, Dalvie, Deepak, Bello, Akintunde, Smith, Bill J.

“…Abstract 1. Crizotinib (XALKORI®), an oral inhibitor of anaplastic lymphoma kinase (ALK) and mesenchymal-epithelial transition factor kinase (c-Met), is…”
Get full text

Evaluation of the effect of ritlecitinib on the pharmacokinetics of caffeine in healthy participants by Liu, Jian, Solan, Rohit, Wolk, Robert, Plotka, Anna, O'Gorman, Melissa T., Winton, Jennifer A., Kaplan, Julia, Purohit, Vivek S.

“…Aims This clinical study was conducted to evaluate the impact of ritlecitinib on the pharmacokinetics of caffeine, a cytochrome P450 1A2 (CYP1A2) substrate…”
Get full text

The Bioequivalence of Tafamidis 61‐mg Free Acid Capsules and Tafamidis Meglumine 4 × 20‐mg Capsules in Healthy Volunteers by Lockwood, Peter A., Le, Vu H., O'Gorman, Melissa T., Patterson, Terrell A., Sultan, Marla B., Tankisheva, Ekaterina, Wang, Qiang, Riley, Steve

“…Tafamidis, a non‐nonsteroidal anti‐inflammatory benzoxazole derivative, acts as a transthyretin (TTR) stabilizer to slow progression of TTR amyloidosis (ATTR)…”
Get full text

Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants by Xu, Huiping, O'Gorman, Melissa T., Nepal, Sunil, James, Lee P., Ginman, Katherine, Pithavala, Yazdi K.

“…Lorlatinib is approved worldwide as treatment for anaplastic lymphoma kinase‐positive and c‐ros oncogene 1‐positive non‐small cell lung cancer. The objectives…”
Get full text

Effects of Renal Function on Crizotinib Pharmacokinetics: Dose Recommendations for Patients with ALK-Positive Non-Small Cell Lung Cancer by Tan, Weiwei, Yamazaki, Shinji, Johnson, Theodore R., Wang, Rong, O’Gorman, Melissa T., Kirkovsky, Leonid, Boutros, Tanya, Brega, Nicoletta M., Bello, Akintunde

“…Background and Objectives Crizotinib (250 mg twice daily) is the first anaplastic lymphoma kinase (ALK) inhibitor approved for treatment of ALK -positive…”
Get full text

A Novel Series of Non-Carboxylic Acid, Non-Hydantoin Inhibitors of Aldose Reductase with Potent Oral Activity in Diabetic Rat Models:  6-(5-Chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and Congeners by Mylari, Banavara L, Armento, Sandra J, Beebe, David A, Conn, Edward L, Coutcher, James B, Dina, Michael S, O'Gorman, Melissa T, Linhares, Michael C, Martin, William H, Oates, Peter J, Tess, David A, Withbroe, Gregory J, Zembrowski, William J

“…Discovery of a highly selective, potent, and safe non-carboxylic acid, non-hydantoin inhibitor of aldose reductase (AR) capable of potently blocking the excess…”
Get full text

A Highly Selective, Non-Hydantoin, Non-Carboxylic Acid Inhibitor of Aldose Reductase with Potent Oral Activity in Diabetic Rat Models:  6-(5-Chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-one by Mylari, Banavara L, Armento, Sandra J, Beebe, David A, Conn, Edward L, Coutcher, James B, Dina, Michael S, O'Gorman, Melissa T, Linhares, Michael C, Martin, William H, Oates, Peter J, Tess, David A, Withbroe, Gregory J, Zembrowski, William J

“…We report here on the discovery path that led to a structurally unprecedented non-hydantoin, non-carboxylic acid aldose reductase inhibitor, 24, which shows…”
Get full text

A Sorbitol Dehydrogenase Inhibitor of Exceptional in Vivo Potency with a Long Duration of Action:  1-(R)-{4-[4-(4,6-Dimethyl[1,3,5]triazin-2-yl)- 2R,6S-dimethylpiperazin-1-yl]pyrimidin-2- yl}ethanol by Mylari, Banavara L, Oates, Peter J, Zembrowski, William J, Beebe, David A, Conn, Edward L, Coutcher, James B, O'Gorman, Melissa T, Linhares, Michael C, Withbroe, Gregory J

“…We report here a novel sorbitol dehydrogenase inhibitor, 16, that shows very high oral potency (50 μg/kg) in normalizing elevated fructose levels in the…”
Get full text

Safety and pharmacokinetics of crizotinib in patients (pts) with hepatic impairment (HI) and advanced cancer by El-Khoueiry, Anthony B., Sarantopoulos, John, O'Bryant, Cindy L., Ciombor, Kristen Keon, Xu, Huiping, O'Gorman, Melissa T, Chakrabarti, Jayeta, Usari, Tiziana, El-Rayes, Bassel F.

“…Abstract only 2552 Background: Crizotinib is a kinase inhibitor approved for treating ALK+ and ROS1+ advanced non-small cell lung cancer. Since crizotinib…”
Get full text

A Novel Series of Non-Carboxylic Acid, Non-Hydantoin Inhibitors of Aldose Reductase with Potent Oral Activity in Diabetic Rat Models:  6-(5-Chloro-3-methylbenzofuran-2-sulfonyl)-2 H -pyridazin-3-one and Congeners by Mylari, Banavara L., Armento, Sandra J., Beebe, David A., Conn, Edward L., Coutcher, James B., Dina, Michael S., O'Gorman, Melissa T., Linhares, Michael C., Martin, William H., Oates, Peter J., Tess, David A., Withbroe, Gregory J., Zembrowski, William J.

Get full text

A sorbitol dehydrogenase inhibitor of exceptional in vivo potency with a long duration of action: 1-(R)-[4-[4-(4,6-dimethyl[1,3,5]triazin-2-yl)- 2R,6S-dimethylpiperazin-1-yl]pyrimidin-2- yl]ethanol by Mylari, Banavara L, Oates, Peter J, Zembrowski, William J, Beebe, David A, Conn, Edward L, Coutcher, James B, O'Gorman, Melissa T, Linhares, Michael C, Withbroe, Gregory J

“…We report here a novel sorbitol dehydrogenase inhibitor, 16, that shows very high oral potency (50 microg/kg) in normalizing elevated fructose levels in the…”
Get full text